Screening of natural product libraries in MCF7 cell line reveals the pro-apoptotic properties of b tetralone

Despite the exponential increase in research toward better treatment options for breast cancer patients, developing an effective drug with fewer side effects continues to remain a challenge. Natural compounds have emerged as a viable option and several drugs have been derived or inspired from them. In this study, we screened a library of natural compounds with diverse chemical structures against selected kinase proteins using in silico methods such as molecular docking and dynamics simulation. The best results were obtained between b tetralone and MDM2 E3 ubiquitin ligase protein. In vitro experiments such as cytotoxicity, scratch assays and flow cytometry analysis using an MCF7 cell line were performed to determine the anti-cancer potential of the compound. As the treatment resulted in cell death and apoptosis, b tetralone was screened in silico against anti-apoptotic targets where the best results were obtained between Bcl-w and b tetralone. This comprehensive study suggests that the anti-cancer activity of b tetralone is probably through the dual targeting of MDM2 E3 ubiquitin kinase and Bcl-w anti-apoptotic protein.

Automated summary

Despite the growing research on breast cancer treatment options, developing an effective drug with minimal side effects remains a challenge. This study screened a library of natural compounds using computational methods to target specific proteins involved in cancer. The compound b tetralone showed promising results against MDM2 E3 ubiquitin ligase and Bcl-w anti-apoptotic protein, indicating its potential as an anti-cancer drug.